Efficacy News and Research

RSS

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.

3 Feb 2010

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

3 Feb 2010

Public policy implications in abstinence-only programs

Study focused on young African American preteens in an urban area: This is a legitimate public health study and it did show that a certain type of abstinence only program can help some very young adolescents (average age 12) delay sexual initiation for up to 24 months.

3 Feb 2010

LExICon study evaluating laser assisted lead removal using Spectranetics laser sheath published

Spectranetics Corporation today announced publication of the four-year, retrospective LExICon (Lead Extraction in Contemporary Settings) study in the February 9th issue of the Journal of American College of Cardiology.

3 Feb 2010

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

In the USA each year, 200,000 cancer patients suffer from a malignant pleural effusion - development of excessive fluid (pleural effusion) in the chest. Several litres of such fluid can accumulate, and many patients suffer from significant breathlessness and distress. One in four patients with lung cancer, one in every three with breast cancer and most of the patients with mesothelioma will develop a malignant effusion.

3 Feb 2010

Research retraction underscores the safety and efficacy of MMR vaccines

The Lancet, a premier British medical journal, today retracted a study published in 1998 that drew a link between the measles, mumps and rubella (MMR) vaccine and increased incidence of autism.

3 Feb 2010

Baker's yeast promising against cancer

A researcher at Charles Drew University of Medicine and Science is investigating the potential use of non-pathogenic baker's yeast as a promising, natural therapy for cancer.

3 Feb 2010

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company’s lead anti-infective and vaccine product candidates.

3 Feb 2010

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.

3 Feb 2010

MV vaccine prevents TB in people with HIV infection

Results from clinical trials conducted in Tanzania show that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection. Findings from the trials, which were conducted by investigators from Dartmouth Medical School in the United States, will be published in the next issue of AIDS, the leading journal in the field of HIV and AIDS research. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

3 Feb 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients.

3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.

3 Feb 2010

Hovione announces filing of new drug application in Japan for the influenza drug CS-8958

Hovione is announcing the filing of a new drug application in Japan by its licensee Daiichi Sankyo Company Ltd. for the influenza drug CS-8958, which is delivered using Hovione's TwinCaps(R) inhaler.

2 Feb 2010

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has been accepted for formal review.

2 Feb 2010

Medco Health Solutions acquires DNA Direct

Committed to being at the forefront of translating personalized medicine from the science to its daily practice in healthcare, Medco Health Solutions, Inc. today announced the acquisition of DNA Direct, Inc., a leader in providing guidance and decision support for genomic medicine to patients, providers, payors and employees.

2 Feb 2010

Overview of newly evolving technologies for diagnosing and monitoring HIV infections

Rising consumer awareness that early diagnosis and treatment can delay the progression of human immunodeficiency virus (HIV) to anti-immuno deficiency syndrome (AIDS) has had a telling impact on the sales of HIV tests.

2 Feb 2010

Efficacy News and Research

Study shows Cymbalta reduces chronic low back pain

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Public policy implications in abstinence-only programs

LExICon study evaluating laser assisted lead removal using Spectranetics laser sheath published

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

Research retraction underscores the safety and efficacy of MMR vaccines

Baker's yeast promising against cancer

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

MV vaccine prevents TB in people with HIV infection

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

Hovione announces filing of new drug application in Japan for the influenza drug CS-8958

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Medco Health Solutions acquires DNA Direct

Overview of newly evolving technologies for diagnosing and monitoring HIV infections

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News